H. Cortés-Funes

Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC)

Ricardo Hitt, Juan J. Grau, Antonio López–Pousa et al. · Journal of Clinical Oncology · 2009 · 69 citations

Neck Cancer, Neoadjuvant Therapy, Cancer Management +18

Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification

H. Cortés-Funes, Immaculada Ales, Arian Benavides Márquez et al. · Journal of Clinical Oncology · 2007 · 55 citations

Her2/neu Overexpression/amplification, Gastric Localization, Phase Ii +13

A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC)

E. Casado, Gunnar Folprecht, L. Paz-Ares et al. · Journal of Clinical Oncology · 2004 · 26 citations

Tumor Biology, Folfiri Regimen, Oral Ekb-569 +15

Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)

José Baselga, M.Á. Climent, Aňa Lluch et al. · European Journal of Cancer Supplements · 2004 · 24 citations

Metastatic Breast Cancer, Breast Oncology, Medicine +9

Phase II/III trial of induction chemotherapy (ICT) with cisplatin/5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs. CRT for unresectable locally advanced head and neck cancer (LAHNC)

Ricardo Hitt, Jaume Grau, Antonio López–Pousa et al. · Journal of Clinical Oncology · 2005 · 18 citations

Neck Cancer, Cancer Management, Surgery +18